WO2014090128A1 - 一种青蒿素环糊精缀合物及其制备方法 - Google Patents
一种青蒿素环糊精缀合物及其制备方法 Download PDFInfo
- Publication number
- WO2014090128A1 WO2014090128A1 PCT/CN2013/088939 CN2013088939W WO2014090128A1 WO 2014090128 A1 WO2014090128 A1 WO 2014090128A1 CN 2013088939 W CN2013088939 W CN 2013088939W WO 2014090128 A1 WO2014090128 A1 WO 2014090128A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cyclodextrin
- artemisinin
- conjugate
- arteannuin
- amine
- Prior art date
Links
- 0 *C1OC1*OI(*)(C(*)(*)I(*)(CC1)C2[C@@](*)(CC3)[C@]1(*)N)O[C@]2O[C@]3(N)OO* Chemical compound *C1OC1*OI(*)(C(*)(*)I(*)(CC1)C2[C@@](*)(CC3)[C@]1(*)N)O[C@]2O[C@]3(N)OO* 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
Definitions
- Artemisinin cyclodextrin conjugate and preparation method thereof TECHNICAL FIELD
- the present invention relates to the field of drug synthesis, and in particular to an artemisinin cyclodextrin conjugate and a preparation method thereof.
- artemisinin has the ability to selectively kill cancer cells, and has minimal effect on normal cells. Artemisinin has a different mechanism of action than traditional tumor chemotherapy drugs, which can reverse the multidrug resistance of tumor cells. There is no cross-resistance to artesunate in leukemia cell lines resistant to doxorubicin, vincristine, methotrexate or hydroxyurea.
- Artemisinin has been used clinically as an anti-malarial drug for many years, and its safety has been confirmed in the application of tens of millions of clinical cases. Its anti-tumor effect is being further studied, which may be related to the reaction of artemisinin with Fe 2+ to produce a large number of free radicals and alkylation, and is also closely related to the induction of tumor cell apoptosis.
- the iron concentration of cancer cells is much higher than that of normal cells.
- the peroxy bridge in the artemisinin structure is catalyzed by iron to generate free radicals, and the cells are killed by the free radical route.
- artemisinin can induce apoptosis in mouse leukemia cancer cells and human liver cancer, but the specific mechanism of stimulation (drug action on target) and effect (apoptosis) is not clear enough. Studies have also suggested that artemisinin has a certain effect on tumor angiogenic factors, and artesunate has broad-spectrum anticancer activity. In vitro studies have shown that artemisinin drugs can inhibit the proliferation of leukemia cells by acting on leukemia P388 cells cultured in vitro. Some artemisinic acid and artemisinic acid compounds have selective inhibitory effects on various tumor cells in vitro. Artemisinin sodium for human cervical cancer
- HeLa cells showed killing effect and had a killing effect on human poorly differentiated squamous epithelial nasopharyngeal carcinoma cells (HeLa, SU E-1 and CNE2), and significantly inhibited the growth of hepatoma cell line BEL-7402.
- the growth of human liver cancer has a significant inhibitory effect.
- Artesunate has the effect of inducing apoptosis of U937 cells, and has a killing effect on human colon cancer cells HCT-8, human erythroleukemia K562 and human breast cancer MCF-7 cell lines.
- artemisininin drugs can also inhibit the growth of human ovarian cancer HO-8910 transplanted tumor, transgenic mouse prostate adenocarcinoma and other tumors.
- artemisinin compounds have poor water solubility and low bioavailability, and cannot be transported to cancer cells. In human and animal models, artemisinin compounds are eliminated faster and cannot form therapeutic doses on cancer cells. .
- Cyclodextrins are semi-natural macromolecular compounds obtained by catalytic degradation of starch by cyclodextrin glucosyltransferase. Cyclodextrins are hardly hydrolyzed and have only a small amount of absorption through the stomach and small intestines of the human body. However, cyclodextrin can be fermented by the organism inside the colon and degraded into monosaccharides or disaccharides, which can be absorbed by the large intestine.
- an artemisinin compound can be bonded to a cyclodextrin compound to form a conjugate, and the artemisinin cyclodextrin conjugate can overcome the inherent disadvantages of artemisinin compounds. Increase the efficacy and reduce side effects.
- an object of the present invention is to provide a targeted artemisinin cyclodextrin conjugation An artemisinin-amino-modified cyclodextrin conjugate.
- the present invention adopts the following technical solutions:
- An artemisininin cyclodextrin conjugate wherein an artemisinin compound and an amine modified cyclodextrin are linked by an amide bond of a carboxyl group of an artemisinin compound with an amine group of an amine modified cyclodextrin .
- conjugate refers to a new molecular entity formed by the covalent bond between two or more molecules.
- the artemisinin cyclodextrin conjugate refers to a compound formed by an artemisinin compound and a cyclodextrin compound (amine-modified cyclodextrin) linked by an amide bond; more specifically And means a compound formed by an artemisinin compound which forms an amide bond with an amine group of a cyclodextrin modified with an amine group.
- the artemisinin-based compound is an artemisinin compound which is formed by substituting c 12 which constitutes an artemisinin molecule with a carboxylic acid-containing compound.
- the synthesis of artemisinin compounds can be carried out in accordance with the prior art in the prior art.
- Cyclodextrin (CD) is a generic term for a series of cyclic oligosaccharides produced by amylose in a cyclodextrin glucosyltransferase produced by Bacillus, which has been studied more and has important practicalities. What is meant is a molecule containing 6, 7, or 8 glucose units, called ⁇ -, ⁇ -, and ⁇ -cyclodextrin, respectively.
- each D(+)-glucopyranose constituting the cyclodextrin molecule is a chair conformation, and each glucose unit is 1 , 4- Glycosidic bonds combine to form a ring. Since the glycosidic bond connecting the glucose unit cannot be freely rotated, the cyclodextrin is a cylindrical three-dimensional ring structure with open ends and a large end at one end and a hollow end. In the hollow structure, the inside of the cavity is formed by the shielding effect of the CH bond.
- the amino group-modified cyclodextrin is a compound formed by substituting an amino group for a hydroxyl group of D(+)-glucopyranose C 2 , C 3 and/or C 6 constituting a cyclodextrin molecule.
- the synthesis of the amine-modified cyclodextrin can be carried out in accordance with the prior literature.
- the cyclodextrin can be first reacted with a sulfonylating reagent to form a sulfonated cyclodextrin [RC Petter, JS Salek, CT Sikorski, G. Kumaravel, and F.-T. Lin: J. Am. Chem. Soc.
- cyclodextrin can undergo cross-acylation at the 2, 3, and/or 6 positions of D(+)-glucopyranose.
- Commonly used sulfonylating agents are phenylphosphoryl chloride and p-nonyl benzene acyl chloride. Then, under the nucleophilic attack of the aminating agent, the sulfonyl group on the acylated cyclized cyclodextrin is removed and replaced with an amine group to form an amine-modified cyclodextrin [B ⁇ . May, SD Kean, CJ Easton, and SF Lincoln: J. Chem. Soc, Perkin Trans. 13157-3160 (1997)].
- the amination reagent may be various kinds of organic reagents containing an amine group, including ammonia, decylamine, ethylamine, propylamine, butylamine, ethylenediamine, ethanolamine, acetamide and diethylenetriamine.
- R 2 and R 3 are -OH or -RNH 2 and at least one of R 2 and R 3 is -RNH 2 ;
- R is (CH 2 ) X , NH(CH 2 ) X , NH(CH 2 ) X NH (CH 2 ) X , CO(CH 2 ) x or
- ⁇ At least 1 means that at least one D(+)-glucopyranose in the amine-modified cyclodextrin molecule is modified by an amine group, wherein m is 5, 6 or 7; and m is 0 means the amine
- the base-modified cyclodextrin constituting the cyclodextrin molecule is modified by an amine group for each D(+)-glucopyranose.
- At least one of Ri, R 2 and R 3 in formula I is -RNH 2 means that the amine-modified cyclodextrin is at least monoamine-modified by an amine-modified D(+)-glucopyranose molecule, which may It occurs at the 2, 3 or 6 position, and may also be a diamine modification or both R 2 and R 3 may be modified.
- R in the amine-RNH 2 of the modified cyclodextrin is (CH 2 ) X , NH(CH 2 ) X , NH(CH 2 ) X NH(CH 2 ) X , CO ( CH 2 ) x or 0(CH 2 ) x represents that the amine group of the modified cyclodextrin may be an organic amine group such as ammonia, decylamine, ethylamine, ethylenediamine, ethanolamine, acetamide or diethylenetriamine, wherein X An integer of 0 or more is preferably 0 to 10, more preferably 0, 1, 2, 3 or 4.
- R is (CH 2) X, NH ( CH 2) X, NH (CH 2) X NH (CH 2) X, CO (CH2) x or 0 (CH 2) x,
- the amine modified cyclodextrin is selected from mono-[6-(ethylenediamino)-6-deoxy]- ⁇ -cyclodextrin, mono-[2-(ethylenediamine) -6-deoxy]- ⁇ -cyclodextrin, mono-[3-(decylamino)-6-deoxy]- ⁇ -cyclodextrin and mono-[6-(ethanolamino)-6-deoxy]- ⁇ fine.
- the artemisinin-based compound is an artemisinin compound which is formed by substituting c 12 which constitutes an artemisinin molecule with a carboxylic acid-containing compound.
- artemisinin compounds can be carried out in accordance with the prior art in the prior art.
- Dihydroartemisinin can react with carboxyl-containing compounds to form artemisinin compounds [PM 0, Neill, et al: J. Med. Chem. 44, 58 - 68 (2001)]
- dihydroartemisinin can be in C
- An etherification or esterification reaction occurs on the hydroxyl group of 12 .
- the etherification or esterification agent may be various compounds containing a hydroxyl group organic group, and the reaction formula is as follows:
- the amine-modified cyclodextrin has a structure represented by Formula II,
- R 4 is (CH 2 ) y , CO(CH 2 ) y , C 6 H 6 (CH 2 ) y or COC 6 H 6 (CH 2 ) y , y is an integer greater than or equal to 0, and CO is a carbonyl group, C 6 H 6 is a benzene ring.
- the etherification and esterification reagents are succinic acid, succinic anhydride, terephthalic acid, p-hydroxybenzoic acid, p-hydroxybenzoic acid ester, p-benzoic acid, para-benzene Tannic acid.
- the artemisinin compound is artesunate, a compound in which a phenoxy group is attached to artemisinin C-12, and a compound in which an alkoxy group is attached to artemisinin C-12.
- Another object of the present invention is to provide a process for the preparation of the artemisinin cyclodextrin conjugate of the present invention.
- a preparation method of the artemisinin cyclodextrin conjugate of the present invention comprises: reacting a carboxyl group of an artemisinin compound with an amine group modified cyclodextrin in a strong polar organic solvent under the action of a condensing agent; The amidation reaction of the amine group produces an artemisinin cyclodextrin conjugate.
- the condensing agent usable in the preparation method of the present invention includes various condensing agents used in the amidation reaction in the pharmaceutical synthesis, and includes a carbodiimide-based condensing agent and a cerium salt-based condensing agent, wherein the carbodiimide-based condensing agent is It is widely used in the preparation of amides for drug synthesis.
- the condensing agent in the production method of the present invention is preferably a carbodiimide-based condensing agent.
- DCC dicyclohexylcarbodiimide
- DIC diisopropylcarbodiimide
- EDCI 1-(3-diamine) Propyl)-3-ethylcarbodiimide
- DCC-HOBt azole complex condensing agent
- the weight ratio of the amine-modified cyclodextrin to the dicyclohexylcarbodiimide is from 1:0.04 to 10, more preferably from 1:0.4 to 5.
- the weight ratio of the amine-modified cyclodextrin to the 1-hydroxybenzotriazole is from 1: 0.03 to 7.5, more preferably from 1:0.3 to 3.
- a dehydrating agent may be used in the amidation reaction of the present invention to absorb water molecules produced by the condensation reaction, to prevent hydrolysis of the condensation product, and to increase the efficiency of the condensation reaction.
- the dehydrating agent includes calcium oxide, phosphorus pentoxide, molecular sieves and the like.
- the amine-modified cyclodextrin is soluble in water and a strong polar organic solvent, while the artemisinin compound, dicyclohexylcarbodiimide and 1-hydroxybenzotriazole are insoluble in water, and the carboxyl group and the amine are
- the amidation of the base is a dehydration condensation reaction, and water as a solvent is disadvantageous to the amidation reaction. Therefore, the preparation method of the present invention uses a strong polar organic solvent as a solvent.
- the strongly polar organic solvent is hydrazine, hydrazine-dimercaptoamide, hydrazine, hydrazine-diethylamide or dimethyl sulfoxide.
- the amidation reaction in the preparation method of the present invention comprises reacting an amine-modified cyclodextrin with an excess of artemisinin compound at - 10 to 10 ° C for 6 to 24 hours to form a carboxyl group activation reaction.
- the intermediate is then reacted at 15 to 40 ° C for 6 to 24 hours to cause amidation of the carboxyl group of artesunate with the cyclodextrin amine group to form an artemisinin cyclodextrin conjugate.
- the preparation method of the present invention further comprises the step of activating the surface hydroxyl group of the amine-modified cyclodextrin before the amidation reaction, comprising reacting the amine-modified cyclodextrin with a condensing agent at -10 to 10 ° C. ⁇ 5h.
- the preparation method of the present invention further comprises the step of purifying the artemisinin cyclodextrin conjugate.
- the purification step according to the present invention may comprise drying the reaction solution obtained by the amidation reaction, collecting the solid residue, dissolving in water, and then filtering The impurities were removed by organic solvent precipitation to obtain a pure artemisinin cyclodextrin conjugate. Wherein the filtration impurity removal is removal of unreacted artesunate, dicyclohexylcarbodiimide and 1-hydroxybenzotriazole.
- the principle of the artemisinin cyclodextrin conjugate prepared by the organic solvent precipitation method is that the organic solvent can lower the dielectric constant of the solution and reduce the polarity of the solvent, thereby weakening the solvent molecule and artemisinin.
- the organic solvent is acetone, decyl alcohol, ethanol, isopropanol, chloroform or tetrahydrofuran.
- the organic solvent precipitation method in the present invention is affected by the concentration of the solution.
- the artemisinin cyclodextrin conjugate precipitates insufficiently, the recovery rate is low, and it is necessary to use a larger proportion of the organic solvent for precipitation; the high concentration solution can save the organic solvent.
- the preparation method of the present invention may further comprise a concentration step to reduce the moisture of the solution, increase the concentration of the solution, and sufficiently precipitate the artemisinin cyclodextrin conjugate in an organic solvent.
- the preparation method of the present invention further comprises the step of refining the artemisinin cyclodextrin conjugate.
- the purification is organic solvent extraction or chromatography.
- the organic solvent is selected from the group consisting of acetone, diethyl ether, chloroform and tetrahydrofuran.
- the invention determines the structure of an artemisinin cyclodextrin conjugate by nuclear magnetic resonance and high resolution mass spectrometry.
- 1 H NMR chart of artemisinin cyclodextrin conjugate showed that 3 ⁇ 4, H 12 , H 13 , H 14 and artemisinin compounds appeared at 0.3 to 3.0 ppm and 5.0 to 7.1 ppm under D 2 0 conditions.
- H 15 characteristic peak while cyclodextrin has no characteristic absorption, and artesunate is almost insoluble in water, which may preliminarily indicate that artesunate reacts with cyclodextrin.
- the artemisinin cyclodextrin conjugate of the present invention uses cyclodextrin as a carrier and artemisinin
- the complex molecule is linked to the cyclodextrin by its own carboxyl group forming an amide bond with any amine group of the amine-modified cyclodextrin.
- the artemisinin cyclodextrin conjugate of the present invention contains more hydrophilic active groups, and has better biocompatibility than artemisinin and dihydrogen blue. Artemisin has better water solubility.
- the artemisinin cyclodextrin conjugate of the present invention has a solubility in water of 25 to 98 mg/mL at 25 ° C, while artemisinin and dihydroartemisinin are hardly soluble in water.
- the artemisinin cyclodextrin conjugate of the present invention has anti-cancer targeting properties, especially for colorectal cancer cell targets.
- the artemisinin cyclodextrin conjugate has only a small amount of absorption through the stomach and small intestine of the human body, can only be decomposed and released in the colonic tract, and then absorbed by the large intestine, and has a colorectal release characteristic.
- the artemisinin cyclodextrin conjugate of the present invention has anti-cancer targeting properties, especially for colorectal cancer cells, and can effectively enter a patient. Prefer aggregation in target cancer cells, selectively induce death of human rectal cancer cells, improve drug efficacy, and reduce toxic side effects.
- a cell suspension of human rectal cancer cells HCT116, Lovo, SW480 and HT29 180 ⁇ l was added to a 96-well culture plate at 5% C0 2 , 37 . C. Pre-culture for 24 h under saturated humidity conditions. After replacing 150 ⁇ l of the medium, 20 ⁇ l of medium containing different concentrations of molecular assemblies was added, and the medium without the sample was used as a negative control to contain different concentrations of camptothecin. The medium of oxaliplatin and fluorouracil was used as a positive control and culture was continued for 48 hours.
- the OD value was measured by the MTT method, and the growth inhibition rate was determined, and the inhibitory effects of the compounds at high, medium, and low concentrations on the proliferation of tumor cells were observed. All of the above experiments were performed in parallel three times. The results show the results of in vitro experiments with artemisinin cyclodextrin conjugates on human rectal cancer cells (as shown in Table 1). Table 1 IC 5 of some artemisinin compounds in several rectal cancer cells. Value ( ⁇ ) (HCT1 16, Lovo, SW480 and HT 90 Cells) IC 50 ( ⁇ ) Compound MW
- cyclodextrin can be decomposed into open-chain maltodextrin, maltose and glucose in the colonic tract, and then absorbed by the large intestine, it can be used as a carrier for colorectal target, and the drug can be directly delivered to the rectum to enhance absorption in the colon.
- the preparation method of the artemisinin cyclodextrin conjugate of the invention has the advantages of easy operation, mild reaction conditions, and can be used for the preparation of the artemisinin cyclodextrin conjugate.
- DRAWINGS Figure 1 shows a nuclear magnetic resonance spectrum (iHNMR) chart of ⁇ -cyclodextrin; Figure 2 shows mono-[2-(ethylenediamine)-6-deoxy]- ⁇ -cyclodextrin-cyan prepared in Example 1.
- the nuclear magnetic resonance spectrum (HNMR) of the artesunate conjugate showed 3 ⁇ 4, H 12 , H 13 , Hi 4 and H 15 characteristic peaks of artesunate at 7-8 ppm, and the cyclodextrin has no characteristics at this point.
- Figure 3 shows the nuclear magnetic resonance spectrum of the mono-[2-(ethylenediamine)-6-deoxy]- ⁇ -cyclodextrin-artesunate conjugate prepared in Example 1 ( 13 CNMR )
- the characteristic unsaturated carbon skeleton absorption peak of artesunate appeared at 10 ⁇ 50ppm, and the amide bond unsaturated carbonyl absorption peak appeared at 170 ⁇ 190ppm;
- Figure 4 shows a high resolution mass spectrum of the mono-[2-(ethylenediamine)-6-deoxy]- ⁇ -cyclodextrin-artesunate conjugate prepared in Example 1 [HSMS(TOF-ESI) ].
- Embodiments of the invention disclose artemisinin cyclodextrin conjugates and methods for their preparation. Those skilled in the art can learn from the contents of this paper and appropriately improve the process parameters. It is to be understood that all such alternatives and modifications are obvious to those skilled in the art and are considered to be included in the present invention.
- the products and methods of the present invention have been described in terms of preferred embodiments, and it is obvious that those skilled in the art can make modifications and/or combinations and combinations of the products and methods described herein to achieve the The technique of the present invention is applied.
- Example 1
- reaction liquid was evaporated to dryness under reduced pressure at 60 ° C, and the residue was dissolved in water, filtered, and the filtrate was concentrated, and the mixture was concentrated to 100 mL of chloroform, and the mixture was filtered, and the precipitate was collected and dried under vacuum at 50 ° C for 24 h to obtain mono-[6- (Ethylene) Amino)-6-deoxy]- ⁇ -cyclodextrin-artesunate conjugate in a yield of 65%. Solubility is 68mg/mL
- the mono-[3-(diethylenetriamine)-6-deoxy]- ⁇ -cyclodextrin 2 mmol was dissolved in anhydrous dimethyl sulfoxide ( 50 mL) and cooled to about -5 °C.
- DCC dicyclohexylcarbodiimide
- HOBT 1-hydroxybenzotriazole
- the mono-[6-(triethylenetetramine)-6-deoxy]- ⁇ -cyclodextrin was dissolved in anhydrous hydrazine, hydrazine-dimercaptoamide (50 mL), and cooled to about 0 °C.
- 1.2 g of dicyclohexylcarbodiimide (DCC) was added, and after stirring for 24 hours in an ice bath, 3.77 g (6 mmol) of a phenoxy group-attached compound of artemisinin C-12 was added, and the reaction solution was stirred at 10 ° C. Stir at 24 ° C for 24 h.
- the mono-[3-(diethylenetriamine)-6-deoxy]- ⁇ -cyclodextrin 2 mmol was dissolved in anhydrous dimethyl sulfoxide ( 50 mL) and cooled to about -5 °C.
- DCC dicyclohexylcarbodiimide
- HOBT 1-hydroxybenzotriazole
- reaction solution was evaporated to dryness under reduced pressure at 60 ° C, and the residue was dissolved in water, filtered, filtrate concentrated, water For eluent column chromatography, the chromatographic solution was collected, concentrated, and dried under vacuum at 50 ° C for 24 h to obtain mono-[6-(triethylenetetramine)-6-deoxy]- ⁇ -cyclodextrin and blue.
- the solubility was 98 mg/mL.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13863004.1A EP2933270B1 (en) | 2012-12-14 | 2013-12-10 | Arteannuin cyclodextrin conjugate and preparing method thereof |
JP2015546831A JP6453761B2 (ja) | 2012-12-14 | 2013-12-10 | アルテアンヌイン−シクロデキストリン結合体及びその製造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210544032.9A CN103864962B (zh) | 2012-12-14 | 2012-12-14 | 基于胺基修饰环糊精的青蒿素前药及其制备方法 |
CN201210544032.9 | 2012-12-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014090128A1 true WO2014090128A1 (zh) | 2014-06-19 |
Family
ID=50904017
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2013/088939 WO2014090128A1 (zh) | 2012-12-14 | 2013-12-10 | 一种青蒿素环糊精缀合物及其制备方法 |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP2933270B1 (zh) |
JP (2) | JP6453761B2 (zh) |
CN (1) | CN103864962B (zh) |
WO (1) | WO2014090128A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017226851A (ja) * | 2012-12-14 | 2017-12-28 | 昆薬集団股▲ふん▼有限公司Kpc Pharmaceuticals,Inc | アルテアンヌイン−シクロデキストリン結合体及びその製造方法 |
CN112111025A (zh) * | 2020-09-28 | 2020-12-22 | 沐荷永康生物科技(云南)有限公司 | 一种大麻二酚环糊精偶合物及其制备方法 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104473918B (zh) * | 2014-11-18 | 2017-04-12 | 昆明理工大学 | 一种键接青蒿琥酯的聚轮烷及其制备方法 |
CN108976318B (zh) * | 2017-06-01 | 2021-03-30 | 首都医科大学 | 单-6-(生物素酰胺基)-6-脱氧-β-环糊精及其制备方法和应用 |
CN108997514B (zh) * | 2017-06-06 | 2021-06-08 | 首都医科大学 | 单-6-(苯达莫司汀酰胺基)-6-脱氧-β-环糊精的制备和应用 |
CN109134709B (zh) * | 2018-07-19 | 2020-08-25 | 昆明理工大学 | 胺基修饰环糊精键接开环葫芦脲的键接物及其制备方法和应用 |
CN113350525B (zh) * | 2021-06-21 | 2022-11-01 | 哈尔滨氧态健康科技有限公司 | 一种多孔淀粉负载青蒿素羟丙基-β-环糊精包合物及其制备方法和应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004075921A1 (en) * | 2003-02-26 | 2004-09-10 | Vrije Universiteit Brussel | Inclusion complex of artemisinin or derivates thereof with cyclodextrins |
CN102716491A (zh) * | 2012-07-02 | 2012-10-10 | 昆明理工大学 | 青蒿素系列物与碱性环糊精的包合物及其制备方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020147177A1 (en) * | 2001-01-24 | 2002-10-10 | Yuen Kah Hay | Formulation of artemisinin |
US6951846B2 (en) * | 2002-03-07 | 2005-10-04 | The United States Of America As Represented By The Secretary Of The Army | Artemisinins with improved stability and bioavailability for therapeutic drug development and application |
CN100479807C (zh) * | 2002-08-15 | 2009-04-22 | 刘云清 | 药物输送系统——固体纳米药物的制备方法 |
FI20065800A0 (fi) * | 2006-12-13 | 2006-12-13 | Glykos Finland Oy | Polyvalentit biokonjugaatit |
CN101125127B (zh) * | 2007-08-16 | 2010-05-19 | 昆明制药集团股份有限公司 | 一种青蒿素类衍生物的冻干制剂及制备方法 |
CN101954090B (zh) * | 2010-09-16 | 2012-11-28 | 桂林南药股份有限公司 | 双氢青蒿素β-环糊精包合物及其制备方法和含有该包合物的抗疟疾药物 |
CN103864962B (zh) * | 2012-12-14 | 2016-04-06 | 昆药集团股份有限公司 | 基于胺基修饰环糊精的青蒿素前药及其制备方法 |
-
2012
- 2012-12-14 CN CN201210544032.9A patent/CN103864962B/zh active Active
-
2013
- 2013-12-10 EP EP13863004.1A patent/EP2933270B1/en active Active
- 2013-12-10 WO PCT/CN2013/088939 patent/WO2014090128A1/zh active Application Filing
- 2013-12-10 JP JP2015546831A patent/JP6453761B2/ja active Active
-
2017
- 2017-08-07 JP JP2017152271A patent/JP2017226851A/ja not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004075921A1 (en) * | 2003-02-26 | 2004-09-10 | Vrije Universiteit Brussel | Inclusion complex of artemisinin or derivates thereof with cyclodextrins |
CN102716491A (zh) * | 2012-07-02 | 2012-10-10 | 昆明理工大学 | 青蒿素系列物与碱性环糊精的包合物及其制备方法 |
Non-Patent Citations (4)
Title |
---|
B.L. MAY; S.D. KEAN; C.J. EASTON; S.F. LINCOLN, J. CHEM. SOC., PERKIN TRANS., 1997, pages 13157 - 3160 |
P. M. 0' NEILL ET AL., J. MED. CHEM., vol. 44, 2001, pages 58 - 68 |
R.C. PETTER; J.S. SALEK; C.T. SIKORSKI; G KUMARAVEL; F.-T. LIN, J. AM. CHEM. SOC., vol. 112, 1990, pages 3860 - 3868 |
R.C. PETTER; J.S. SALEK; C.T. SIKORSKI; G. KUMARAVEL; F. -T. LIN, J. AM. CHEM. SOC., vol. 112, 1990, pages 3860 - 3868 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017226851A (ja) * | 2012-12-14 | 2017-12-28 | 昆薬集団股▲ふん▼有限公司Kpc Pharmaceuticals,Inc | アルテアンヌイン−シクロデキストリン結合体及びその製造方法 |
CN112111025A (zh) * | 2020-09-28 | 2020-12-22 | 沐荷永康生物科技(云南)有限公司 | 一种大麻二酚环糊精偶合物及其制备方法 |
CN112111025B (zh) * | 2020-09-28 | 2022-08-16 | 云南佩林科技有限公司 | 一种大麻二酚环糊精偶合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
EP2933270A1 (en) | 2015-10-21 |
CN103864962B (zh) | 2016-04-06 |
CN103864962A (zh) | 2014-06-18 |
JP2016503078A (ja) | 2016-02-01 |
JP6453761B2 (ja) | 2019-01-16 |
EP2933270A4 (en) | 2016-07-20 |
EP2933270B1 (en) | 2017-09-06 |
JP2017226851A (ja) | 2017-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014090128A1 (zh) | 一种青蒿素环糊精缀合物及其制备方法 | |
EP1580216B1 (en) | High-molecular weight derivatives of camptothecins | |
CN101289482B (zh) | 藤黄酸苷衍生物和类似物及其制备方法和用途 | |
WO2008010463A1 (fr) | Conjugué polymère d'une combrétastatine | |
JP6509969B2 (ja) | シクロデキストリンキャリアベースのアルテアンヌイン化合物複合体及びその調製方法 | |
CN114057692A (zh) | 一种杂环类化合物、其制备方法及用途 | |
CN109021026A (zh) | 顺铂药物前体、制备方法和应用 | |
CN108478804B (zh) | 一种聚丙烯酸-s-s-药物共聚物及其制备方法 | |
CN111467500B (zh) | 一种低氧双靶向性agt抑制剂偶联物及其制备方法与应用 | |
CN101613386B (zh) | 藤黄酸环合类似物及其制备方法和应用 | |
CN103627772B (zh) | 一种雷公藤内酯醇衍生物的制备方法及其产物和应用 | |
CA2446429C (en) | Aloe-emodin derivatives and their use in the treatment of neoplastic pathologies | |
CN108976318B (zh) | 单-6-(生物素酰胺基)-6-脱氧-β-环糊精及其制备方法和应用 | |
CN102671213B (zh) | 一种灯盏花乙素前药及其制备方法 | |
CN110922450B (zh) | Psma激活式抗肿瘤前药cpt-x及其制备方法和应用 | |
CN111518040B (zh) | 一种甲基吡嗪衍生物-哌嗪共晶 | |
CN112138001A (zh) | 一种槲皮素-低分子肝素-紫杉醇结合物、制备方法及应用 | |
CN113024557A (zh) | 一种Peganumine A生物碱结构简化物及其应用 | |
WO2015199555A1 (en) | Polymers for coating nanoparticles | |
CN111303175B (zh) | 一种10-羟基喜树碱类衍生物及其制备方法、药物、应用 | |
CN117924404B (zh) | 一种基于雷公藤红素的protac化合物、制备方法及应用 | |
WO2004080453A1 (ja) | 抗c型肝炎ウイルス剤と抗hiv剤 | |
KR20220059436A (ko) | 신규한 공결정, 이를 포함하는 약학 조성물 및 이의 제조 방법 | |
CN114874217A (zh) | 苯并氮杂卓衍生物的盐、溶剂合物、多晶型物、制备方法及应用 | |
CN113024449A (zh) | 一种含金属的高效阳离子抗肿瘤药物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13863004 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2015546831 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2013863004 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013863004 Country of ref document: EP |